Data and AI for the pharmaceutical industry: from regulatory traceability to explainable AI to explainable AI

In an industry where every claim needs a source and every process must be auditable, scattered data isn’t just a technical problem. It’s a regulatory risk.

Veltech connects your organization’s knowledge so AI answers with traceability, not just probability.

·

Traceability by design

·

Auditable AI

·

EMA · FDA · GxP

Certified partners

Snowflake neo4j Databricks Google Cloud Azure

The core challenge

In pharma, AI can’t give probable answers. It has to give traceable ones

Generating answers isn’t the problem; any model can do that. The problem is that in a regulated environment, every claim needs a source, every process needs an audit trail, and every decision has to be explainable. That isn’t an AI problem. It’s a data problem.

Research and development

Scattered experimental knowledge doesn’t scale

Clinical trial data, scientific literature, and lab results sit in separate systems. Scientists spend more time searching than discovering. With a [knowledge graph], scientific questions get real context.

Regulatory affairs

Agency submissions take months of manual consolidation

CTD, PSUR, DSUR. Every dossier requires consolidating data from multiple systems with full traceability. A [governed data platform] turns that consolidation into a continuous process, not a sprint before every submission.

Manufacturing and quality

Process data isn’t connected to product quality data

Without that connection, deviation investigations and CAPAs are labor-intensive, and the link between process parameters and quality attributes has to be rebuilt every time.

Enterprise AI

AI agents answer fluently, but not traceably

In a GxP environment, an answer that can’t be cited isn’t valid, not for scientists and not for regulators. [Governed AI agents] change that.

A real case from our portfolio

Generating answers wasn’t the problem; the models were already doing that. The problem was that those answers were probable, not traceable, and in a regulated industry that isn’t enough. We modeled the organization’s explicit knowledge as a [graph]: which source supports which claim, which regulatory relationship connects each data point. The result wasn’t faster AI, but AI that could show where every answer came from.

Consulting project in the pharmaceutical industry · Veltech

Why pharma is different

Three reasons the data standard in this industry is higher

01

Traceability isn’t optional: it’s regulatory

ALCOA+, 21 CFR Part 11, Annex 11. Data must be attributable, legible, contemporaneous, original, and accurate. Not as an aspiration, but as an inspection requirement.

02

The drug lifecycle generates data volumes few industries can match

From molecule to market: preclinical, Phase I/II/III trials, regulatory approval, post-market pharmacovigilance. Each phase generates different data that must be connected without losing the context of the phases before it.

03

A data error isn’t a technical incident: it’s a risk to patients

That’s why [data governance] isn’t an IT priority. It’s a business priority and a matter of regulatory accountability.

Regulatory framework

Designed for what regulators already require

Data architecture and governance are designed around these frameworks from day one, not added as a layer at the end.

EMA / FDA

Data traceability for marketing authorization dossiers and pharmacovigilance reports (PSUR, DSUR).

GxP

GMP, GCP, GLP: data integrity across manufacturing, clinical trials, and laboratory research.

21 CFR Part 11 · Annex 11

System validation and audit trails for electronic records in regulated environments.

GDPR

Management of clinical trial subject and patient data, with full traceability of access and processing.

RECORDED WEBINAR

Graphs for business: from siloed data to competitive advantage

Discover how graphs organize enterprise data and give you full visibility across your business.

Frequently asked questions

Before you request the assessment

What’s usually the first use case with a pharmaceutical company?

It depends on the area, but the most common are traceability for regulatory dossiers (when a registration or renewal cycle is approaching) and explainable AI for R&D or regulatory affairs teams. The initial assessment helps decide which one will have the most impact for each organization.

The architecture design includes system validation requirements (IQ/OQ/PQ) and the audit trail mechanisms that regulated environments require, from the very start of the project.

Yes, with the anonymization and access control measures required by GDPR and the trial protocols, built into the architecture design from the start.

Yes, our approach adapts to the size and stage of each organization. The data challenges of a clinical-stage biotech differ from those of a commercial-stage pharma company, and we tailor the approach in each case.

NEXT STEP

Discover how to turn your organization’s knowledge into explainable AI

A no-obligation initial assessment, tailored to your area and where you are today in data maturity.